{"transactions":[{"id":1665744,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":94789,"kind":"person","name":"MITCHELL DANIEL J","position":1,"cik":"0001113661","reported_name":"MITCHELL DANIEL J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-01-31T21:25:36.000Z","date":"2024-01-30","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of January 30, 2024, subject to the Reporting Person continuing to provide Continuous Service (as defined in the 2020 Equity Incentive Plan) through such date. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested."}],"balance_after":6000,"derivative":{"exercise_price":1.64,"expiration_date":"2034-01-30","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-24-002480","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919124002480/doc4.xml","form_type":"4"}},{"id":2082556,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":94789,"kind":"person","name":"MITCHELL DANIEL J","position":1,"cik":"0001113661","reported_name":"MITCHELL DANIEL J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-12-19T21:24:51.000Z","date":"2022-12-15","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of December 15, 2022.  If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested."}],"balance_after":6000,"derivative":{"exercise_price":2.32,"expiration_date":"2032-12-15","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-22-061919","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919122061919/doc4.xml","form_type":"4"}},{"id":2908765,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":94789,"kind":"person","name":"MITCHELL DANIEL J","position":1,"cik":"0001113661","reported_name":"MITCHELL DANIEL J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-01-14T00:05:18.000Z","date":"2021-01-12","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 36 equal monthly installments beginning as of December 21, 2020.  If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested."}],"balance_after":12000,"derivative":{"exercise_price":4.31,"expiration_date":"2031-01-12","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-21-003469","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919121003469/doc4.xml","form_type":"4"}},{"id":4017298,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":94789,"kind":"person","name":"MITCHELL DANIEL J","position":1,"cik":"0001113661","reported_name":"MITCHELL DANIEL J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-03-05T22:33:32.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant to the Reporting Person of a stock option under the 2013 Amended and Restated Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of January 1, 2018.  If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested."}],"balance_after":8000,"derivative":{"exercise_price":0.72,"expiration_date":"2028-02-29","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-18-016689","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919118016689/doc4.xml","form_type":"4"}},{"id":4336018,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":94789,"kind":"person","name":"MITCHELL DANIEL J","position":1,"cik":"0001113661","reported_name":"MITCHELL DANIEL J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-05-03T20:08:07.000Z","date":"2017-05-02","kind":"purchase","acquired":true,"shares":11000,"price":2.71,"value":29810.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from\n$2.65 to $2.75. Upon request of the SEC staff, ARCA biopharma, Inc. (the \"Company\") or a security holder of the Company, the reporting person\nwill provide full information regarding the number of shares purchased at each separate price."}],"balance_after":11000,"source":{"system":"sec-edgar","filing":"0001209191-17-029621","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919117029621/doc4.xml","form_type":"4"}},{"id":4437402,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":94789,"kind":"person","name":"MITCHELL DANIEL J","position":1,"cik":"0001113661","reported_name":"MITCHELL DANIEL J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-02-21T21:53:00.000Z","date":"2017-02-16","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant to the Reporting Person of a stock option under the 2013 Amended and Restated Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of January 1, 2017.  If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested."}],"balance_after":8000,"derivative":{"exercise_price":2.5,"expiration_date":"2027-02-15","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-17-012763","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919117012763/doc4.xml","form_type":"4"}}]}